Alexion Pharmaceuticals' (ALXN) Soliris gets Orphan Drug Designation for the treatment of the...

|About: Alexion Pharmaceuticals, Inc. (ALXN)|By:, SA News Editor

Alexion Pharmaceuticals' (ALXN) Soliris gets Orphan Drug Designation for the treatment of the rare neurological disorder neuromyelitis optica for which there are no approved treatments. The drug "significantly" reduced relapse frequency in a Phase 2 study. Last month, SA contributor Todd Campbell predicted that "additional Soliris indications [could] support future sales growth." (PR)